DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer—Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989
2.
Chabner B.: Pharmacologic Principles of Cancer Treatment. Philadelphia, PA, Saunders, 1982
3.
Dorr RT, Fritz WL: Cancer Chemotherapy Handbook. New York, NY, Elsevier, 1980
4.
Haskell CM (ed): Cancer Treatment. Philadelphia, PA, Saunders, 1980
5.
Ignoffo RJ: Neoplastic disorders, in Young LY , Koda-Kimble MA (eds): Applied Therapeutics—The Clinical Use of Drugs (ed 4). San Francisco, CA, Applied Therapeutics , 1988;pp 1085-1114
6.
Rubin R (ed): Clinical Oncology: A Multidisciplinary Approach (ed 6). American Cancer Society, 1983
7.
Saenz RV, Saenz RV: Basic concepts of cancer chemotherapy. US Pharmacist Aug/Sept:24-30, 26-33, 56, 1979 .
8.
See-Lasley K., Ignoffo R.: Manual of Oncology Therapeutics. St Louis, MO, Mosby, 1981
9.
Casciato DA, Lowiitz BB (eds): Manual of Clinical Oncology (ed 2). Boston, MA,Little, Brown, 1988
10.
Abramowicz M (ed): Cancer chemotherapy. Med Lett Drugs Ther31:49-56, 1989
11.
Balducci L. , Parker M., Sexton W., et al: Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol16:76-84, 1989
12.
Balis FM, Poplack DG: Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol11:74-86,1989
13.
Balis FM, Holcenberg JS, Bleyer WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet8:202-232, 1983
14.
Bender RA, Zwelling LA, Doroshow JH, et al: Antineoplastic drugs: Clinical pharmacology and therapeutic use. Drugs16:46-87, 1978
15.
Calabresi P. , Chabner BA: Chemotherapy of neoplastic diseases, in Gilman AG, Rall TW, Nies AS, et al (eds): The Pharmacological Basis of Therapeutics . (ed 8). New York, NY, MacMillan, 1990, pp 1202-1263
16.
Chabner BA, Myers CE, Coleman CN, et al: The clinical pharmacology of antineoplastics. N Engl J Med292:1107-1113, 1159-1167, 1975
Henriksson R., Grankvist K.: Interactions between anticancer drugs and other clinically used pharmaceuticals. Acta Oncol28:451-462, 1989
21.
Scholtz JM: Cancer chemotherapy, Part I and II. Am Druggist March/April:135-145, 137-148, 1987
22.
Phister JE, Jue SG, Cusack BJ: Problems in the use of anticancer drugs in the elderly. Drugs37:551-565, 1989
23.
Walsh SJ, Begg CB, Carbone PP: Cancer chemotherapy in the elderly. Semin Oncol16:66-75, 1989
24.
Loehrer PJ: Current developments and future direction with ifosfamide. Semin Oncol16:1-101, 1989
25.
Brade WP, Herdrich K., Varini M.: Ifosfamide-Pharmacology, safety and therapeutic potential. Cancer Treat Rev12:1-47,1985
26.
Zalupski M. , Baker LH: Ifosfamide. J Natl Cancer Inst80:556-566, 1988
27.
Schoenike SE , Dana WJ: Ifsofamide and mesna. Clin Pharm9:179-191, 1990
28.
Schein PS, O'Connell MJ, Blom J., et al: Clinical tumor activity and toxicity of streptozotocin. Cancer34:993-1000, 1974
29.
Bleyer WA: Methotrexate: Clinical pharmacology, current status and therapeutic guidelines . Cancer Treat Rev4:87-101, 1977
30.
Arbuck SG: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer63:1036-1044, 1989
31.
Bleyer WA: New vistas for leucovorin in cancer chemotherapy. Cancer63:995-1007, 1989
32.
Grem JL: 5-fluorouracil plus leucovorin in cancer therapy. Updates: Principles & Practice of Oncology.7:1-12, 1988
33.
Moran RG: Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthetase. Cancer63:1008-1012, 1989
34.
Urba S., Forastiere A.: Systemic therapy of head and neck carcinoma: Most effective agents and areas of controversy. Oncology3:79-88, 1939
35.
Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med322:352-358, 1990
36.
Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large bowel carcinoma. An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol7:1447-1456, 1989
37.
Spreafico F. : Use of levamisole in cancer patients. Drugs19:105-116,1980
38.
Mayer RJ: Dose adjuvant therapy work in colon cancer?N Engl J Med322:399-401,1990
39.
Smith BD: Antitumor update: Vinca alkaloids and epipodophyllotoxins. Hosp Formul22:363-368, 1987
40.
Fleming RA, Miller AA, Stewart CF: Etoposide: An update. Clin Pharm8:274-293, 1989
41.
O'Dwyer RJ, Leyland-Jones B., Alonso MT, et al: Etoposide (VP-16-213): Current status of an active anticancer drug. N Engl J Med312:692-700,1985
42.
Phillips NC , Lauper RD: Review of etoposide. Clin Pharm2:112-119,1983
43.
Sinkule JA: Etoposide: A semisynthetic epipodophyllotoxin. Pharmacotherapy4:61-73,1984
44.
Goodman TL: Antibiotics in cancer chemotherapy: The anthracyclines. Hosp Formul21:444-455, 1986
Foster BJ, Harding BJ, Wolpert-Defilippes MK, et al: A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. Cancer Chemother Pharmacol25:395-404,1990
47.
VanEcho DA, Egorin MJ, Aisner J.: The pharmacology of carboplatin. Semin Oncol16:1-6, 1989
48.
Woloschuk DM , Pruemer JM, Cluxton RJ: Carboplatin: A new cisplatin analog. Drug Intell Clin Pharm22:843-849, 1988
49.
Koeller J., Eble M.: Mitoxantrone: A novel anthracycline derivative. Clin Pharm7:574-581, 1988
50.
Paciucci PA , Cuttner J., Holland JF: Mitoxantrone as a single agent and combination chemotherapy in patients with refractory acute leukemia . Semin Oncol11:50-53, 1984
51.
Saletan S.: Mitoxantrone: An active, new antitumor agent with an improved therapeutic index. Cancer Treat Rev14:297-303, 1987
52.
Wohciechowski NJ, Carter CA, Skoutakis VA, et al: Leuprolide: A gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm20:746-751, 1986
53.
Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med311:1281-1286, 1984
54.
Vance MA, Smith JA: Endrocrine and clinical effects of leuprolide in prostatic cancer . Clin Pharmacol Ther36:350-354, 1984
55.
Labrie F., DuPont A., Giguere M., et al: Combination therapy with flutamide and castration (orchiectomy or LHRH agonist). J Steroid Biochem27:525-532, 1987 56. Kassem NY, Neri RO: Flutamide in advanced cancer of the prostate . Clin Pharmacol Ther31:238-241, 1982 57. Geller J., Albert J., Vik A.: Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol15:53-61, 1988
